Catalyst Biosciences

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time.

Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs

Myers

Office Depot

Vicor

Increased analyst coverage over the last few weeks might led to solid price appreciation for stocks like ODP (ODP), Myers (MYE), Catalyst Biosciences (CBIO), Vicor (VICR) and Bally's (BALY).

5 Stocks to Keep an Eye on as Analysts Initiate Coverage

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020. The pre-recorded presentation is available for registered attendees via the Piper Sandler conference site until December 3. It will also be available on the Events and Presentations section on the Company's website for approximately 90 days.

Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference

Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is administered intravenously, whilst Catalyst's candidates can be administered subcutaneously - a key advantage.

Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next

Castle Biosciences Inc

Inmode Ltd

Universal Forest Products

VeriSign

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Biosciences (CSTL).

5 Stocks Set to Pop on New Analyst Coverage

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or MarzAA, the Company's subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 62nd Annual American Society of Hematology (ASH) meeting being held virtually December 5-8, 2020.

Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer, and Clinton Musil, chief financial officer, of Catalyst Biosciences will present at the Stifel 2020 Virtual Healthcare Conference taking place on November 16-18, 2020. Details for the company presentation are as follows:

Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference

CB 2782-PEG patent protection extended until at least 2038 CB 2782-PEG patent protection extended until at least 2038

Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases

SOUTH SAN FRANCISCO, Calif., Sept.  25, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: “The evolution of complement targeted therapies,” taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time.

Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit

SOUTH SAN FRANCISCO, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer and Clinton Musil, chief financial officer of Catalyst Biosciences, will participate in fireside chats at two investor conferences in September: The Morgan Stanley Global Healthcare Conference and the Cantor Virtual Global Healthcare Conference. Details for each can be found below.

Catalyst Biosciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update

Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels

Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress

SOUTH SAN FRANCISCO, Calif., July  01, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today reported that the Compensation Committee of Catalyst’s Board of Directors granted a non-qualified inducement stock option to purchase an aggregate of 140,000 shares of Catalyst’s common stock to Clinton Musil, Catalyst’s recently appointed Chief Financial Officer, effective July 1, 2020.

Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June  29, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the Russell 2000® Index effective at the U.S. market open today, June 29, 2020.

Catalyst Biosciences Added to Russell 2000 Index

SOUTH SAN FRANCISCO, Calif., June  22, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Mr. Charles Democko as Senior Vice President, Regulatory Affairs.

Catalyst Biosciences Appoints Charles Democko, Senior Vice President, Regulatory Affairs

CB 2679d-GT demonstrates robust expression of FIX in multiple preclinical models CB 2679d-GT demonstrates robust expression of FIX in multiple preclinical models

Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020

SOUTH SAN FRANCISCO, Calif., June  15, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Clinton Musil as its new chief financial officer, effective July 1, 2020.

Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June  15, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced final efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of Hemophilia B. The poster was presented at the World Foundation of Hemophilia Virtual Summit, taking place from June 14 -19, 2020.

Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of Hemophilia Virtual Summit 2020

SOUTH SAN FRANCISCO, Calif., June  12, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Raymond James Human Health Innovation Conference at 3:00 pm ET on Thursday, June 18, 2020.

Catalyst Biosciences Present at the Raymond James Human Health Innovation Conference

Results support subcutaneous dosing regimen of the Phase 3 Registrational trial Results support subcutaneous dosing regimen of the Phase 3 Registrational trial

Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study

SOUTH SAN FRANCISCO, Calif., June  08, 2020  (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of Hemophilia Virtual Summit, taking place from June 14-19, 2020.

Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback

Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update

FIX patent including DalcA and CB 2679d-GT, now issued in all major markets FIX patent including DalcA and CB 2679d-GT, now issued in all major markets

Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio

Final results to be presented during the second quarter Final results to be presented during the second quarter

News for Catalyst Biosciences Stock (CBIO)